Ayahuasca

Ayahuasca’s effects arise from a complex interplay of compounds. The primary psychoactive, DMT, is a potent agonist at serotonin 5-HT2A receptors (with substantial partial activity at 5-HT2C【10†L314-L322】, and some binding at 5-HT1A and the σ1 receptor)【43†L232-L239】. The co-administered β-carbolines (harmine, harmaline, THH) from B. caapi are potent reversible MAO-A inhibitors【34†L253-L259】. This MAO-A blockade prevents first-pass catabolism of DMT, making oral dosing active【30†L200-L209】【31†L1-L4】. By comparison to IV or smoked DMT (onset seconds, ~15–30min duration), ayahuasca’s effects come on more slowly and last ~3–4h【38†L502-L506】. Pharmacokinetic studies show DMT’s plasma half-life is only ~0.6h when combined with harmine【19†L1-L4】, though harmine’s own half-life (~1.4h) prolongs the overall experience. In healthy volunteers, C_max of DMT is reached ~75min post-ingestion【12†L508-L516】. Dose-response has been characterized mostly in small studies, but subjective intensity rises with DMT/harmine dose; one first-in-human trial found that higher intranasal DMT+oral harmine doses produced proportionally stronger psychedelic ratings without new safety signals. Neurobiologically, ayahuasca suppresses default-mode network connectivity【34†L225-L234】 and alters activity in limbic and visual areas. Post-dose, it elevates peripheral biomarkers of plasticity: for example, blood BDNF levels rise significantly by 24–48h【4†L388-L392】. Animal models also show DMT stimulates hippocampal neural progenitors and angiogenesis, suggesting a broad neurotrophic mechanism【43†L232-L239】.

Ayahuasca’s origins trace back millennia among Amazonian tribes, but its compounds entered scientific awareness in the mid-20th century. In 1956 Hungarian chemist Stephen Szára was the first to synthesize DMT and self-administer it, noting its vivid effects. Traditional use continued largely unreported in Western science until ethnobotanists (e.g. R. Evans Schultes in the 1940s) brought attention to the brew. DMT was later placed in UN Schedule I (1971)【60†L138-L142】, which stifled research. Meanwhile, the Santo Daime and União do Vegetal churches incorporated ayahuasca into syncretic rituals, and Brazil legally exempted ayahuasca for religious use in 1987【28†L453-L459】. The late 20th century saw sporadic studies: Grob et al. (1996) tested the safety of harmine in humans; Callaway (1999) elucidated MAO interactions; Riba and colleagues (early 2000s) performed controlled pharmacology and neuroimaging studies. The modern research renaissance really took hold in the 2010s. Key publications include open-label trials of ayahuasca in depression (Osório et al. 2015; Sanches et al. 2016) and the first placebo-controlled RCT (Palhano-Fontes et al. 2019)【27†L403-L410】. These followed rising general interest in psychedelics, new funding (e.g. Heffter Foundation support), and advances in brain-imaging methods. In 2026, Erritzoe et al. reported the first controlled trial of DMT infusion for depression【24†L274-L281】, cementing ayahuasca’s relevance. Institutional milestones include the 2006 U.S. Supreme Court ruling (UDV v. Gonzales) allowing religious ayahuasca use【64†L304-L312】 and major labs taking up ayahuasca studies (e.g. Maastricht Univ., Imperial College London, Federal U. of Rio Grande do Norte). In short, ayahuasca research evolved from anthropological notes to pharmacological characterization, a hiatus under prohibition, then a sophisticated revival in clinical neuroscience over the past decade.

The safety profile of ayahuasca in controlled settings is generally favourable. In pooled analyses of clinical trials (over 100 administrations), the most common adverse events were expected serotonergic effects: gastrointestinal upset (nausea, vomiting, diarrhea), transient headaches, and mild-to-moderate increases in heart rate and blood pressure【70†L426-L434】. Some participants experience acute anxiety, confusion or dysphoria during the peak, but there are no reports of lasting psychosis or cognitive deficits【70†L426-L434】【70†L431-L437】. Critically, no serious organ toxicities or fatalities have been documented in the literature. In the pivotal 2019 TRD study, 100% of patients vomited, but none suffered lasting harm, and all reported feeling physically safe during the session【69†L7-L10】. No tolerance or dependence has been observed even with repeated ceremonial use. Contraindications include personal or family history of psychosis or bipolar disorder, uncontrolled cardiovascular disease, and pregnancy. Drug–drug interactions are important: co-use with SSRIs, SNRIs or MAO inhibitors can precipitate serotonin syndrome or hypertensive crises【70†L411-L418】. Lithium is also avoided (risks of seizures seen with other psychedelics). Because ayahuasca inherently contains MAOIs, standard dietary restrictions (low tyramine) are often recommended. There is no approved REMS or formal guidance, but best practice involves thorough screening, medical monitoring during ceremonies, and integration support. In general, a comfortable, supportive set-and-setting is emphasised to mitigate the mild anxiety or “challenging” experiences that may occur【69†L7-L10】【70†L431-L437】.

The most advanced indication is major depressive disorder (especially TRD). Ayahuasca’s rapid-onset mood effects (evident by 24–72h post-dose) make it a candidate for TRD or severe acute depression. Ongoing trials will clarify optimal dosing/frequency and whether effects sustain beyond one or two doses. Other indications in development: PTSD is being tested (e.g. Brazilian Phase II NCT07317206) due to anecdotal reports of trauma processing. Substance use disorders (alcohol, opioids, stimulants, nicotine) show promise from observational data【68†L1877-L1881】; formal trials are planned in some addiction clinics. Preliminary cases suggest potential in eating disorders: a small case series reported fewer binge-eating days after ayahuasca【4†L384-L392】. Controlled research is very limited for these emerging uses, but the pilot data encourage further study. Neurologic/degenerative applications are speculative: DMT’s neurogenic effects in animals hint at Alzheimer’s or TBI research interest, but no human studies exist. In all cases, patient selection will likely exclude psychotic or unstable personalities. Importantly, clinicians note that set-and-setting (psychological preparation and integration) appears crucial to outcomes, and this non-pharmacologic component will be an important focus of future protocols.